Figure 1.

Study flowchart. We screened 2795 consecutive patients with cognitive complaints from the departments of neurology or psychiatry and psychotherapy of the University Hospital Erlangen from 2009 until 2018. There were 372 patients with either CAA, Alzheimer’s disease, MCI due to Alzheimer’s disease, MCI with unlikely Alzheimer’s disease, or without neurological or psychiatric disease primary related to amyloid deposition and normal cognitive tests results (healthy controls), and available MRI and CSF biomarkers eligible for outcome analyses. Abbreviations: CAA, Cerebral amyloid angiopathy; CSF, Cerebrospinal fluid; MCI, Mild cognitive impairment